Effective treatments and animal models for the most prevalent neurodegenerative form of blindness in the elderly, called age-related macular degeneration (AMD), are lacking. Genome-wide association studies have identified lipid metabolism and inflammation as AMD-associated pathogenic pathways. Given liver x receptors, encoded by NR1H3 and NR1H2, are master regulators of these pathways, herein we investigated the role of LXR in human and mouse eyes as a function of age and disease, and tested the therapeutic potential of targeting LXR. We identified immunopositive LXR fragments in human extracellular early dry AMD lesions and a decrease in LXR expression within the retinal pigment epithelium (RPE) as a function of age. Aged mice, lacking LXR presented with isoform dependent ocular pathologies. Specifically, loss of the Nr1h3 isoform results in pathobiologies aligned with AMD, supported by compromised visual function, accumulation of native and oxidized lipids in the outer retina, and upregulation of ocular inflammatory cytokines, while absence of Nr1h2 is associated with ocular lipoidal degeneration. Therapeutically, LXR activation, ameliorated lipid accumulation and oxidantinduced injury in RPE cells in vitro, and decreased ocular inflammatory markers and lipid deposition in a mouse model, in vivo, providing translational support for pursuing LXR-active pharmaceuticals as potential therapies for dry AMD.
Introduction 64
Dysregulated lipid metabolism and inflammation are key contributors to the development of 65 multiple diseases of aging including the ocular neurodegenerative disease, age-related macular 66 degeneration (AMD), a leading cause of blindness in the elderly in the Western and developing 67 Worlds, that affects over 130 million people in toto (1, 2) . A hallmark of the "early" dry clinical 68 sub-type of AMD is choriocapillary dropout (3) as well as accumulation of lipid-and protein-rich 69 deposits, known as drusen, below the retinal pigment epithelial (RPE) layer, support cells to the 70 retina (4, 5) . While the pathogenesis of early dry AMD remains to be fully understood, an array 71 of risk factors have been identified, cueing disease-associated signaling pathways, most notably, 72 age, along with environmental (e.g. smoking), and genetic factors (e.g. genes associated with 73 inflammatory, complement, and lipid regulating pathways) (6) (7) (8) (9) . In spite of the wealth of accepted 74 knowledge regarding potential risk factors, treatment options remain tenuous for patients suffering 75 from the "early" dry form of AMD. Therefore, there is a considerable need to not only identify 76 critical signaling pathways that drive the initiation and progression of AMD, but also to develop 77 appropriate animal models that could then be used as a platform to test potential therapies and 78 further discover disease regulating pathways. 79 Nuclear receptors are the largest family of transcription factors in the human genome that 80 facilitate the expression of a variety of genes important in maintaining cellular homeostasis during 81 development and aging (10, 11) . Importantly, they play a regulatory role in diseases of aging 82
including Alzheimer's disease (12, 13) , cardiovascular disease (14) , and cancer (15) . Given the 83 commonality between pathogenic pathways regulated by nuclear receptors in age-related diseases 84 and AMD, in an attempt to identify candidate receptors that may be important in disease initiation 85 and progression, we previously developed a nuclear receptor atlas of human RPE cells, cells 86 vulnerable in AMD (16) . The liver X receptor (LXR; NR1H), emerged as a promising target, in 87 light of its role as a regulator of cholesterol homeostasis (17, 18) and inflammation (18) , two 88 pathways modulated in AMD (19) . Further justification for investigating the role of LXR in the 89 aging eye comes from genome-wide association studies, which have found a correlation between 90 single nucleotide polymorphisms in genes involved in cholesterol metabolism/transport and AMD, 91
including member 1 of human transporter sub-family ATP binding cassette transporter (ABCA1), 92 cholesteryl ester transfer protein (CETP), hepatic triglyceride lipase C (LIPC), and lipoprotein 93 lipase (LPL) (9, 20, 21) , known LXR target genes (22) . 94
To test the hypothesis that the LXR signaling pathway regulates AMD pathology and may 95 serve as a potential target for therapy, we interrogated the role of the LXR pathway in ocular cells 96 vulnerable in AMD. We evaluated the expression of LXR in human RPE cells derived from donor 97 eyes as a function of age, examined the distribution of LXR in human donor eyes as a function of 98 disease, and compared LXR expression throughout compartments of the ocular posterior pole. 99 Activation of the receptor was further evaluated in vitro, under AMD relevant stressed conditions 100 with pharmacologic LXR ligands. The ocular function and phenotype of aged mice lacking the 101 LXR isoforms (Nr1h3 −/− , Nr1h2 −/− and Nr1h3 −/− /Nr1h2 −/− ) were catalogued and the therapeutic 102 potential of activating the LXR signaling pathway on the 'AMD' phenotype, including 103 extracellular lipid accumulation and inflammation in the back of the mouse eye, was tested. We 104 report a decrease in NR1H3 expression in human RPE cells as a function of age, and accumulation 105 of LXR immunopositive fragments within drusen of dry AMD eyes, reinforcing vulnerability to 106 AMD development through this pathway. We found that LXR activating ligands are able to 107 improve mitochondrial function, and decrease lipid load in RPE cells following injury. 108
Furthermore, we established that the absence of LXR effects the visual function and ocular 109 phenotype of mice differentially, with the Nr1h3 isoform resulting in the accumulation of 110 extracellular lipid-and protein-rich deposits, phenotypic features of dry AMD, while the Nr1h2 111 isoform also resulted in non-AMD phenotypes, namely stellate cataract formation and RPE 112 associated lipoidal degeneration. Detailed analysis of mouse eyes lacking Nr1h3 revealed a pro-113 inflammatory microenvironment, as evidenced by the accumulation of immune cells in the outer 114 retina, and confirmed through analysis of the cytokine profile of the mouse RPE-choroid. Finally, 115 LXR activation was able to reduce AMD relevant pathogenic phenotypes including posterior pole 116 ocular inflammation and lipid deposition in mice expressing apoB100, a model for aging and early 117 AMD-associated phenotypes (23, 24) . 118
Our studies collectively, highlight the importance of the NR1H3 signaling pathway in the 119 health of aged RPE cells, and present a novel mouse model for the dry AMD phenotype featuring 120 lipid rich sub-RPE deposits along with accumulation of sub-retinal immune cells. This model may 121 serve as a platform to test new therapies and identify additional therapeutic targets. Importantly, 122 our results provide translational support for approaches including direct activation of the LXR 123 pathway, which is capable of reducing AMD associated pathologies and may be a therapeutic 124 target for not only the early dry form of AMD, but also other ocular and non-ocular diseases 125 characterized by either abnormal lipid deposition or tissue immune cell infiltration. 126 expression in human RPE cells ( Figure 1B and Figure S1B ). In a smaller cohort of RPE tissue 141 from middle to advanced aged donors, expression of LXR target genes ABCA1 (n=12) and APOE 142 (n=15) were found to increase with age ( Figure S2A and S2B). The purity of freshly isolated RPE 143 cells from human donors was assessed by measuring the expression of bestrophin-1 (BEST1) and 144 retinal pigment epithelium specific protein 65/retinoid isomerohydrolase RPE65 (RPE65) freshly 145 isolated RPE, retina and choroid from corresponding donors. RPE samples (n = 23) were found to 146 have a 2.13 X 10 2 -4.52 X 10 5 fold higher expression of BEST1 and 4.98 X 10 2 -2.15 X 10 4 fold 147 higher expression of RPE65, relative to ARPE19 cells. Additionally, the expression levels of 148 BEST1 and RPE65 in retina and choroid were negligible (0.01 -0.3 fold change for BEST1 and 149 0.009 -0.2 fold change for RPE65) as compared to the RPE samples, reflecting the purity of the 150 samples. Importantly, all the components of the LXR pathway were expressed in freshly isolated 151 tissue and cultured cells ( Figure 1C ). We next evaluated the localization of NR1H3 and ΝR1Η2 152 protein in retinal cross-sections from 'AMD and age-matched non-effected 'normal' donor eyes 153 via immunohistochemistry. In sections from non-effected donors, NR1H3 immunoreactivity was 154 observed in RPE cells and select cones ( Figure 1D , 1E, 1F), while NR1H2 immunoreactivity was 155 also present throughout the inner retina ( Figure 1J , 1K and 1L). In AMD donor sections, NR1H3 156 immunoreactivity was less evident in the RPE cell layers ( Figure 1G , 1H, and 1I) but still present, 157 though at lower levels, and NR1H3 immunopositive fragments were seen in large drusen in 6 out 158 of 9 donor tissues ( Figure 1 and S3 ), in addition to cone cells as shown by R/G opsin staining 159 ( Figure S4 ). This staining pattern was confirmed using a different primary antibody to NR1H3 160 ( Figure S4 ). NR1H2 immunoreactivity in drusen was also abundant in addition to diffuse staining 161 within the neural retina of AMD eyes, reflecting the ubiquitous nature of this isoform ( Figure 1M , 162
1N and 1O). 163
The LXR pathway is biologically active in AMD vulnerable cells 164 NR1H3 and NR1H2 activities were examined in human primary RPE cells (hRPE), and the 165 macaque derived RF/6A choroidal endothelial cell (CEC) lines. Receptor transcriptional activity 166 was assessed by measuring the binding of the receptor-ligand complex to the gene response 167 element using a luciferase reporter assay. Ligand activation by GW3965 and TO901317, two non-168 steroidal LXR active pharmaceuticals (Table S3 ), significantly increased LXR promoter activity 169 in hRPE (GW3965: 4-fold, TO901317: 2-fold; Figure 2A ) and CEC (GW3965: 2.5-fold, 170 TO901317: 5-fold; Figure 2D ) cells. This induction was reversed following siRNA induced 171 knockdown of NR1H3 and NR1H2 expression. Conversely, LXR antagonist (GSK2033) treatment 172 did not result in promoter binding. Ligand activation by GW3965 and TO901317, significantly 173 induced expression of LXR target genes, fatty acid synthase (FASN) and sterol regulatory element-174 binding protein 1 (SREBF1) in both hRPE (from a 93 year old, female; Figure 2B Collectively, these results demonstrate that components of the LXR pathway are expressed, and 178 LXR activity and target gene expression can be modulated through the use of pharmacological 179 drugs and siRNA, respectively, in ocular cells vulnerable in AMD. Furthermore, variation in the 180 magnitude of LXR induction and expression, illustrates the differential nature and cell-specific 181 effects of these ligands. 182
LXR activation differentially ameliorates oxidant injury and lipid overload in a ligand 183 dependent manner in the eye 184
The retina is susceptible to oxidant injury culminating from inadequate neutralization of generated 185 reactive oxygen species (ROS). This high ROS load is a consequence of the retina's daily exposure 186 to visible light, its high oxygen consumption, the daily phagocytosis of photoreceptor outer 187 segments, as well as its polyunsaturated fatty acid-rich environment (25) . Human RPE cells were 188 exposed to agents simulating oxidant injury [i.e. NaIO3, H2O2, and cigarette smoke extract (CSE)], 189 and lipid overload [i.e palmitic acid (PA) and alpha linolenic acid (αLA); Table S3 ]. The effects 190 of LXR modulation in response to oxidant-and lipid-induced damage to the RPE cells were 191 determined by evaluating the activity assay, mitochondrial membrane potential using the JC-1 192 assay, lipid buildup in the cells by adipored assay and cell viability by CellTiter-Blue® assay. We 193 found that the treatment with oxidant injury and lipids did not directly induce LXR activity in RPE 194 cells ( Figure S5 ). Therapeutically, a 24-hour pre-treatment of RPE cells with the LXR ligand, 195 TO901317 was able to prevent the compromise to the mitochondrial membrane potential in NaIO3, 196 H2O2, and CSE treated cells, whereas GW3965 pretreatment was able to block mitochondrial 197 injury in lipid treated cells ( Figure 3A by pretreatment with GW3965 ( Figure 3B ). The agonist TO901317, and antagonist GSK2033, did 203 not impact lipid accumulation in RPE cells in vitro. Finally, cell viability assessments confirmed 204 that the drug pretreatments and injury treatments were sub-lethal for the course of the assay (Figure  205 3C). These results revealed the therapeutic potential of activating the LXR pathway to avert 206 oxidant injury and lipid accumulation in RPE cells. Importantly, the two LXR agonists tested 207 appear to work via distinct pathways, as evident by their selective action in response to diverse 208 injury agents. 209
Loss of Nr1h3 in vivo compromises visual function 210
Given the role of LXR in regulating lipid metabolism and inflammation, two pathways associated 211 with development of AMD, and our observation that LXR expression in human RPE cells 212 decreases with age, we examined the visual function of aged LXR knockout mice, after confirming 213 that the absence of LXR globally also effects LXR gene expression locally in the RPE/choroid 214 ( Figure S7 ). Visual function was assessed by recording ERGs from 10-14 month old Nr1h3 -/-(n = 215 11), Nr1h2 -/-(n = 11), Nr1h3 -/-/Nr1h2 -/-(n = 2), and Nr1h3 +/+ /Nr1h2 +/+ wildtype (WT, n = 15) 216 controls. Evaluation of the ERG recordings revealed a decline in scotopic a-wave (approximately 217 41%), scotopic b-wave (approximately 26%), and photopic b-wave amplitudes (approximately 218 28%) of Nr1h3 -/mice compared to WT controls ( Figure 4A , 4B, and 4C), indicating that in the 219 absence of Nr1h3, visual function may be compromised at several levels, including the 220 photoreceptors, and retinal cells post-synaptic to photoreceptors. We also evaluated the visual 221 function of Nr1h3 -/mice as a function of age and observed an age-related decline in scotopic a-222 wave and b-wave amplitudes (4-5 month olds compared to 10-12 month olds; Figure S8 Figure S10 ). However, a significant decline (24.9%) in 227 the c-wave amplitude in Nr1h3 -/mice compared to WT controls ( Figure 4D ) was observed, 228 reflecting the contribution of the RPE to the visual function decline observed in these mice (26) . 229
While Nr1h2 -/mice did not display any gene-specific differences in visual function, the Nr1h3 -/-230 /Nr1h2 -/mice followed a similar trend to the Nr1h3 -/mice ( Figure 4 ). Finally, no significant 231 isoform specific differences were seen in dark adaptation and a-wave flash sensitivity. Some LXR 232 dependent changes in the recovery kinetics for a-wave amplitude were seen, but only at early time 233 points ( Figure 4E and 4F). 234
Isoform specific ocular pathologies indicate absence of LXRα is associated with an early dry 235

AMD phenotype 236
In vivo imaging allowed examination of the morphology of the fundus and OCT images from aged 237
Nr1h3 -/-, Nr1h2 -/-, and Nr1h3 -/-/Nr1h2 -/and WT controls. Whereas the fundus and OCT images 238 from the WT mice were not remarkable ( Figure 5A and 5B), the Nr1h3 -/mice exhibited hypo-239 pigmented regions in the fundus ( Figure 5C , 5D, S11A, S11B, S11C, S11D, S11E, S11F, S11G, 240 and S11H). Similarly, Nr1h3 -/-/Nr1h2 -/mouse fundus images, presented with pigmentary changes 241 in the fundus ( Figure 5G and 5H). Nr1h2 -/mice, in addition to retinal changes, developed stellate 242 cataracts ( Figure 5E , 5F, and S11I, S11J, S11K and S11L), resulting in cloudy fundus images. The 243 overall architecture of the inner retinas of LXR null mice were evaluated ex vivo in cross-sections 244 and no gene specific differences in the overall architecture and thickness of the inner retinal layers 245 were found [Nr1h3 -/-(n = 5), Nr1h2 -/-(n = 3), Nr1h3 -/-/Nr1h2 -/-(n = 4) and WT (n = 4); Figure 5I , 246 5J, 5K, 5L, S10]. High magnification evaluation of the outer retina of LXR mice using cTEM 247 allowed for detailed analysis of the ultrastructure of the RPE-choroid complex. While eyes from 248
WT mice exhibited normal RPE-choroid morphology with organized basal infoldings and apical 249 processes of the RPE ( Figure 5M and 5N ), in Nr1h3 -/mice, continuous sub-RPE deposits were 250 observed below disrupted basal infoldings, seen as amorphous electron dense material, 251 interspersed with 'streamers', a phenotype typical of early dry AMD (over 40% of the length of 252 BrM; Figure 5O , 5P and S12). The RPE phenotype of Nr1h2 -/mice had distinct pathologies 253 including accumulation of large lipid droplets within the RPE, reminiscent of lipoidal 254 degeneration, which is not a characteristic of AMD ( Figure 5Q and 5R) (27, 28) . Predictably, 255
Nr1h3 -/-/Nr1h2 -/mice, displayed both phenotypes, large lipid droplets within the RPE in 256 combination with accumulation of extracellular electron-dense sub-RPE deposits ( Figure 5S and 257 5T). Based on these morphological findings we conclude that in the eye the alpha isoform of LXR 258 regulates extracellular lipid deposition, an early phenotypic feature of dry AMD, while the beta 259 isoform is responsible for intracellular lipid accumulation as well as stellate cataract, an ocular 260 pathology of the anterior segment. 261
Nr1h3 regulates lipid deposition in the outer retina 262
Accumulation of neutral lipids with age in Bruch's membrane and extracellular to the RPE has 263 been correlated with drusen formation (29, 30) . Given the reported role of LXR in regulating lipid 264 metabolism, we stained cryosections from Nr1h3 -/-(n = 4), Nr1h2 -/-(n = 4), Nr1h3 -/-/Nr1h2 -/-(n = 265
3) and WT (n = 3) mice with the histochemical stain oil red o (ORO) in order to evaluate the 266 presence of neutral lipids within the retina. While the RPE and BrM of WT mice was absent of 267 neutral lipids ( Figure 6A ), Nr1h3 -/mice displayed robust staining in sub-RPE deposits and within 268 BrM ( Figure 6B ). Nr1h2 -/mice displayed a strong globular staining pattern within and below the 269 RPE cell layer ( Figure 6C ). Nr1h3 -/-/Nr1h2 -/mice also displayed strong ORO positive staining not 270 only within the RPE cells but also in sub-RPE deposits ( Figure 6D ). ORO positive staining in the 271 tips of the photoreceptor outer segments, as seen in the WT panel served as a positive internal 272 control ( Figure 6A ). Another characteristic of sub-RPE deposits in AMD is the accumulation of 273 apolipoprotein E (APOE), a regulator of cholesterol transport, and oxidized lipoproteins (31, 32) . 274
Probing Nr1h3 -/-(n = 4), and WT (n = 3) eyes with antibodies targeting APOE and oxidized 275 phosopholipids present in oxidized LDL (E06), revealed higher levels of APOE and E06 276 immunoreactivity below the RPE in Nr1h3 -/-( Figure 6F ) compared to WT sections ( Figure 6E Figure 6M and S13D). A region of the Nr1h3 -/-BrM, which lacked the accumulation of these 286 spherical particles is also shown ( Figure 6N ). Given that the choriocapillaris is also compromised 287 in dry AMD, we also visualized the ultrastructure of the choriocapillary (CC) surface and found 288 that in wild type mice, fenestrations in the CC appear as circular pores or "wagon wheels" (Figure 289 S14A, S14B, S14E and S14F), but in Nr1h3 -/mice, fewer fenestrations were observed, and the 290 "spokes" of the fenestrations were fewer in the "wagon wheels" (Figure S14C, S14D, S14G and 291 S14H). These results provide a unique representation of lipid deposition in regions below the RPE 292 and details of changes in RPE morphology associated with the loss of Nr1h3. Finally, an evaluation 293 of RPE autofluorescence revealed a similar isoform-dependent pattern of severity, with significant 294 upregulation seen in Nr1h3 -/-(16.7%) and Nr1h3 -/-/Nr1h2 -/-(20.0%) compared to the WT (Figure  295 6O, 6P, 6Q, 6R and 6S) mice and no significant changes seen in Nr1h2 -/-RPE autofluorescence 296 levels. These findings suggest that lipofuscin accumulation in the RPE cells, which may be a result 297 of dysregulation of lipid metabolism and clearance, as well as accumulation of extracellular neutral 298 lipid, and apolipoprotein are at least in part attributable to Nr1h3. 299
Nr1h3 -/mice exhibit a pro-inflammatory microenvironment in the outer retina 300
In addition to regulating genes involved in cholesterol transport, LXR is involved in regulation of 301 an array of pro-inflammatory genes resulting as a consequence of insults such as 302 lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), or 303 bacterial stimulation (18) , and it has been reported that LXR agonists may act as negative 304 regulators of macrophage inflammatory gene expression (37) . Of relevance, recruitment of 305 immune cells to the outer retina are a purported feature of the AMD etiology (38) . We examined 306 the outer retina of Nr1h3 -/mice for inflammatory mediators. RPE-choroid flat mounts were 307 prepared from aged WT (n = 5) and Nr1h3 -/-(n = 8) mice, probed with a macrophage marker 308 (ADGRE1, also known as F4/80) and stained with phalloidin to delineate the RPE cells. We 309 observed a 3.8-fold accumulation of ADGRE1 + cells within the sub-retinal space of Nr1h3 -/-310 compared to WT mice ( Figure 7A , 7B, 7C and 7D), suggesting an augmented pro-inflammatory 311 microenvironment in the sub-retinal space. However, we did not detect striking differences in the 312 morphology of phalloidin stained RPE cell borders ( Figure S15A , S15B and S15C). To further 313 evaluate the cytokine milieu of the outer retina, we examined the cytokine profile of the RPE-314 choroid tissue complex isolated from WT and Nr1h3 -/mice. Out of a panel of 62 proteins, Nr1h3 -315 /samples exhibited a significant upregulation of nine cytokines, with a primarily pro-316 inflammatory profile ( Figure 7E and 7F) . Interestingly, at a systemic level, 10 cytokines were 317 found to be downregulated in the plasma of Nr1h3 -/mice ( Figure S16A and S16B). These results 318 corroborate that Nrlh3 is involved in maintaining a homeostatic microenvironment in the outer 319 retina. 320
Therapeutic targeting of LXR diminishes pathogenic phenotypes associated with AMD 321
There is marked accumulation of neutral lipids in the pentalaminar BrM in a normal eye with aging 322 (39, 40) . This lipid buildup in the posterior eye has been theorized to set the stage for the formation 323 of extracellular lipid rich deposits and specifically the development of drusen and basal deposits, 324 phenotypic characteristics of early dry AMD (39, 41, 42) . Several studies have shown that this 325 extracellular lipid deposition is at least in part, due to the accumulation of esterified cholesterol-326 rich apolipoprotein B (APOB) -containing lipoprotein particles (43, 44) . Since mice 327 predominantly produce the apoB48 protein, we employed a mouse that produces the full-length 328 mouse apoB100 (23), as a proof of concept, to evaluate the therapeutic effect of modulating LXR 329 activity. It is well established that the RPE-choroid of young apoB100 mice, produce the apoB100 330 isoform and there is accumulation of neutral lipids in their BrM (24) . Herein, three month old 331 apoB100 mice were fed a low fat diet (LFD) or the LXR agonist GW3965, supplemented in a low 332 fat diet (LFD + GW), for a period of 5 months. Mice in both groups displayed a similar rate of 333 increase in weights with age, suggesting absence of any overt systemic toxicities ( Figure S17A) . 334
We measured the expression of LXR target genes, Abca1 and Srebp1c in RPE-choroid isolated 335 from LFD and LFD + GW treated mice and found that their expression was upregulated in the 336 LFD + GW cohort (Abca1: 54%, Srebp1c: 35%, n=2), indicating that the drug was able to reach 337 the posterior retina and activate LXR locally. Additionally, no differences were observed in the 338 systemic levels of HDL and LDL/VLDL ( Figure S17B and S17C). Fundus and OCT imaging 339 exhibited an improvement in the morphology of retinal layers as evident by a decrease in hypo-340 pigmented regions in fundus images of LFD + GW group ( Figure 8C and 8D) as compared to LFD 341 mice ( Figure 8A and 8B) . We also observed a significant decrease in GFAP staining within the 342 inner retina following activation of LXR in comparison to mice fed the LFD, supporting rescue of 343 retinal injury associated with the apoB100 mice and a decline in inflammation ( Figure 8E and 8F) . 344
Quantification of the lipoprotein deposition in BrM of apoB100 mice revealed a significant 345 decrease (77%) in the fraction of APOE + length of BrM, following LXR agonist treatment ( Figure  346 8G, 8H, and 8I). GW3965 treatment also led to a reduction in the number of ADGRE + cells within 347 the sub-retinal space (81%, p=0.0598; Figure 8J , 8K, and 8L). Furthermore, examination of the 348 ultrastructure of the retina/RPE/choroid complex from vehicle (LFD; Figure 8M ) and drug-treated 349 mice (LFD + GW) revealed disrupted RPE basal infoldings ( Figure 8N The need to identify animal models that recapitulate early phenotypic features of complex 364 neurodegenerative diseases such as dry AMD is a necessity to serve as a platform to not only 365 further understand the pathobiology of disease, but also facilitate testing of potential therapies in 366 pre-clinical studies. We hypothesized that the LXR signaling pathway is likely an important 367 mediator of AMD pathobiology given its role as a regulator of lipid metabolism, lipid transport, 368 and inflammation, critical pathogenic pathways associated with disease development. To this end, 369 we interrogated human ocular samples from AMD donors for evidence of LXR involvement and 370 found that the expression of LXR in human RPE cells, nurse cells to the retina and a primary 371 vulnerable site in AMD, decreases as a function of age. Furthermore, we found that drusen, the 372 characteristic lesion of early dry AMD contain fragments that are LXR immunopositive. We This study is the first comprehensive characterization of the posterior ocular function and 386 phenotype of LXR knockout mice. Though redundancies have been shown in the function of the 387 two LXR isoforms in other organs including the liver, isoform specific functions have also been 388 discovered. Systemically, aged LXR deficient mice have been shown to display isoform specific 389 differences in plasma cholesterol levels, with absence of Nr1h2, associated with significant 390 elevation of total cholesterol and HDL levels and absence of either Nr1h3 or Nr1h2 associated 391 with increased LDL levels (45) . Additionally, Nr1h3 -/mice have been shown to display rapid 392 accumulation of large amounts of cholesterol, leading to impaired hepatic function (46) . 393
Conversely, Nr1h2 -/mice maintain their resistance to dietary cholesterol, despite differences in 394 the expression of genes involved in lipid metabolism (47) . Similarly, differences in expression of 395 target genes have been reported in the epididymis of 12 month old mice, with the absence of the 396 beta isoform but not alpha associated with a significant loss of expression of the cholesterol 397 transporters, Abca1 and Abcg1 (45) . In our investigations, we found that the LXR pathway must 398 also be critical for the development of normal visual function, as visual function deficits, mostly 399 corresponding to the posterior region of the eye and specifically the RPE, were detected. 400 Importantly, decrease in the function of RPE cells was primarily observed in mice deficient in the 401
Nr1h3. Furthermore, we found that both isoforms, along with their obligate binding partners, the 402 RXRs, are expressed in several ocular tissues of the posterior pole including the retina, RPE, and 403 choroid. Isoform specific variations were also found in physiological and pathological processes 404 under the control of each of the isoforms in the eye. Absence of Nr1h2 effected the anterior 405 segment resulting in stellate cataract formation as well as accumulation of intracellular and 406 extracellular lipid deposits, while Nr1h3 null mice primarily developed RPE extracellular lipid 407 accumulation. When both isoforms were absent, not surprisingly, not only were all phenotypes 408 evident but also life expectancy was diminished with many mice perishing by 10-11 months of 409 age. 410
That the LXR signaling pathway may be important in the aging eye is not surprising, given 411 the importance of cholesterol regulation in the retinal milieu. The retina relies on both local 412 synthesis as well as delivery from systemic circulation to replenish its cholesterol reserves (48, 413 49 ). Furthermore, it employs HDL-mediated reverse cholesterol transport and metabolism of 414 cholesterol to more soluble oxysterols for its elimination (49, 50) . The excess cholesterol may 415 remain in the retina and undergo oxidation as a result of exposure to light and endogenous free 416 radicals (51, 52) . Given the fact that LXRs, key regulators of cholesterol homeostasis, are 417 expressed in retina and RPE and, oxysterols act as endogenous ligands for LXRs, it is plausible 418 that LXRs may be the principal regulators of lipid metabolism and transport in the eye. This was 419 confirmed by our in vivo assessments, which show accumulation of neutral and oxidized lipids 420 below the RPE and within BrM, as evident by positive ORO and E06 staining in the absence of 421
Nr1h3. Accumulation of oxidized lipids is an important contributor to AMD pathogenesis as these 422 oxidized lipids can directly contribute to tissue injury or recruit inflammatory mediators in the 423 outer retina (53) . QFDE TEM is an imaging technique which has previously been used to visualize 424 lipid particles, believed to be lipoproteins in human aged donor eyes (54) . In conjunction with 425 conventional TEM we were able to study the topology and ultrastructure of lipid deposits in detail 426 in the RPE/BrM complex. While normal and healthy RPE basal infoldings in the WT mice were 427 seen, Nr1h3 -/mice displayed regions of severely disrupted basal infoldings amidst healthy regions. TNFα, or, IL-1β stimulation (37) . In our study, we have shown the accumulation of ADGRE1 + 447 macrophages in the outer retina of Nr1h3 -/mice, indicating a pro-inflammatory micro-448 environment. We also measured the cytokine profile of the RPE-choroid complex and found a 449 proinflammatory cytokine profile in Nr1h3 -/mice compared to the WT mice. This panel of 450 cytokines includes IGFBP3, IGFBP5, IL12 P70, IL13, CCL9, CXCL2, SELP, CCL5 and LEPR. 451 IGF-axis gene polymorphisms have been associated with advanced AMD and specifically IGFBP3 452 and IGFBP5 have been shown to be expressed in RPE progressive phenotypes, namely normal, 453 early reactive, and myofibroblasts (57, 58) . IL13 levels have also been found to be upregulated in 454 the aqueous humor of patients diagnosed with neovascular AMD, suggesting a pathological role 455 in AMD progression (59) . CCL9 and CXCL2 have been reported to be involved in the recruitment 456 of neutrophils to the site of injury and might act as a chemoattractant for the ADGRE1 + 457 macrophages (60) . Furthermore, CCR5 shows a trend to be elevated in a subset of monocytes 458 isolated from treatment naive neovascular AMD patients (61) . Interestingly, we observed that 459 systemic levels of cytokines significantly decreased in Nr1h3 -/mice compared to the controls, 460 some with reported protected properties. CXCL1 has been reported to confer a neuroprotective 461 function in a model of experimental autoimmune encephalomyelitis (62) . CSF1 has been 462 implicated in repair following acute kidney injury suggesting that a decline in systemic CSF1 463 levels may have a detrimental effect on tissue homeostasis (63) . The contrary trend seen in RPE-464 choroid and systemic levels of IGFBP3, CCL9 and CXCL2, together with the ocular phenotype 465 observed in knockout mice implies that local cytokine milieu may have a more dominant role in 466 maintaining homeostasis and/or contributing to disease, especially in an organ such as the eye, 467 which enjoys immune privilege. Though it remains to be seen if the inflammation observed in 468 these mice is a direct consequence of the absence of LXR or if it occurs in response to the elevated 469 lipid accumulation, we construe that loss of Nr1h3 leads to a pro-inflammatory ocular 470 environment, which may aid in the progression of the disease by altering RPE and/or choroidal 471 endothelial cells. 472
Finding and developing therapies for dry AMD has been a challenge to date. This dilemma 473 is in part, due to the complexity of this neurodegenerative disease, with multiple retinal cells 474 affected and pathogenic pathways involved, raising the question of which cells and/or pathways 475 should be targeted. One strategy has been to target genetic risk factors or modify environmental 476 factors associated with disease progression. An alternative strategy would be to strengthen the 477 armor of AMD-vulnerable cells and reinforce pathways that are compromised as a function of age. 478
We found that expression of LXRs decreases as a function of age and, in particular, in the 'elderly' 479 risk age-group, supporting the hypothesis that activating LXR may have beneficial effects on the 480 overall health of RPE cells. Two factors must be considered in pursuing pre-clinical testing of an 481 LXR targeted therapy. 482
The first is the choice of activating ligand. To date, several activating LXR ligands have 483 been reported to modulate lipid metabolism and inflammatory pathways in different injury models, 484 including the eye. Activating LXR with GW3965, has been shown to provide a protective effect 485 in experimental diabetic retinopathy and an inner retinal damage mouse model (56, 64) , while the 486 LXR agonist TO901317 has been shown to ameliorate amyloid β-induced inflammatory responses 487 in human RPE cells as well as the neural retina (65, 66) . It is important to note however, that LXR 488 ligands, are not without side-effects, most notably temporary hyper-triglyceridemia. Furthermore, 489 the TO901317 compound, the first LXR ligand to be identified and one that has been tested 490 frequently by researchers, has potential off target effects through activation of other nuclear 491 receptors including FXR and PXR (67, 68) . The selectivity of LXR ligands can be attributed to 492 several factors, including degree of induction of genes involved in lipid transport, namely ABCA1, 493 ABGA1, APOE; or trans-repression of proinflammatory genes such as nitric oxide synthase 494 (iNOS), cyclooxygenase-2 (PTGS2), or proinflammatory cytokines in microglia and astrocytes 495 (47, 69, 70) . It has further been proposed, but unproven that GW3965 and TO901317 may bind to 496 both isoforms with varying degrees of binding affinity (71) . In our studies, in vitro assays allowed 497 comparison of the function of agonists GW3965 and TO901317, versus the antagonist GSK2033 498 in RPE and choroidal endothelial cells. We found these activating ligands bind to both isoforms, 499 NR1H3 and NR1H2, as evident by the induction of promoter activity and target gene expression, 500 in the presence of siRNA targeting individual isoforms. Our in vitro, AMD-relevant endpoints for 501 assessing LXR ligand efficacy, included mitochondrial membrane potential, as a measure of 502 mitochondrial health, and lipid accumulation. The choice to assess the mitochondria was in light 503 of the extensive evidence supporting a contributory role of mitochondrial dysfunction, changes in 504 mitochondrial number and size, increased mitochondrial DNA damage and a decline in DNA 505 damage repair in AMD (72) (73) (74) (75) . Furthermore, the mitochondrial enzyme cytochrome P450 27A1 506 (CYP27A1), regulates cholesterol homeostasis, bile acid biosynthesis, activation of vitamin D3, 507 and removal of the cytotoxic metabolite 7-ketocholesterol, and it absence in mice results in 508 upregulation of cholesterol biosynthesis in the mouse retina, along with sub-RPE accumulation, 509 (76, 77) , supporting additional contributions of mitochondrial function to AMD pathogenesis. We 510 found that the ability of LXR activation to prevent mitochondrial injury when RPE cells are 511 exposed to multiple oxidative insults, including treatment with sodium iodate, hydrogen peroxide, 512 cigarette smoke extract, and lipid overload was selective and based on the type of oxidant injury. 513 TO901317, was effective in countering 'classical' oxidant injury such as NaIO3, H2O2 and CSE 514 whereas, GW3965 was effective in ameliorating mitochondrial injury induced by lipid treatment. 515
Similarly, we found that only GW3965 was able to prevent intracellular lipid accumulation in 516 response to treatment with PA and αLA in RPE cells. 517
The second factor to be considered for pre-clinical studies is the choice of animal model. 518
We tested the therapeutic effect of LXR activation on lipid deposition and inflammation in the 519 apoB100 mouse model, which is characterized by accumulation of neutral lipids below the RPE 520 (24), a phenotypic feature of aging and potential precursor to development of AMD. Furthermore, 521 in these mice, the cholesterol transporter, apoE, also accumulates below the RPE in the space 522
where sub-RPE deposits develop (32) . We chose to deliver the drug via diet, as systemic delivery 523 of LXR ligands have been used to target the brain and both GW3965 and TO901317 have been 524 shown to pass the blood-brain-barrier (78, 79) . We observed that apoB100 mice fed a diet rich in 525 GW3965 for 5 months display a decline in expression of inflammatory markers (GFAP and 526 ADGRE1) within the retina, and, apolipoprotein E deposition within Bruch's membrane, 527
supporting the therapeutic potential of targeting LXR to target these AMD associated pathologies. 528
Several studies to date have examined the phenotype of tissue specific knockdown of 529 downstream target genes of the LXR, including ABCA1 in photoreceptor and RPE cells (80, 81) . 530
In the absence of Abca1 in mouse photoreceptors, there is accumulation of neutral lipid rich sub-531 retinal debris and Aif1 + sub-retinal cells, along with compromise in visual function (81) also seen in our Nr1h2 -/mice (80) . Given previous findings that Abca1 levels are impacted more 535 so in the absence of the beta isoform than alpha, it is plausible that downstream effectors other 536 than Abca1 may be involved in the accumulation of lipids extracellular to RPE cells (e.g. the lipid-537 rich drusen phenotype). Additionally, phenotypic characterization of Nr1h2 -/mice, which exhibit 538 inflammation of the optic nerve and loss of ganglion cells with aging, suggests that the beta isoform 539 is a major contributor to the regulation of inflammation in the inner retina (82) . Ban et al targeted 540
the lipid efflux pathway in macrophages by deleting Abca1 and Abcg1, and found that the double 541 knockout mice present with extracellular lipid-rich deposits in the outer retina, below the retina, 542 concomitant with photoreceptor dysfunction (83) . Collectively, these reports in conjunction with 543 our results support that both LXR isoforms are involved in the regulation of inflammation and 544 lipid deposition in inner and outer retina, but in an isoform-specific manner and the need for future 545 studies examining the impact of LXR using tissue specific knockout models. 546
Overall, our study establishes the LXR pathway as a key regulator of lipid transport and 547 inflammation in the eye. Aged mice lacking the alpha isoform represent a new mouse model of 548 the dry AMD phenotype and may be used as a platform to test therapies specifically targeting 549 excess extracellular lipid accumulation and inflammation. Further, we identified mechanisms of 550 LXR-based therapies and demonstrated in vivo efficacy of targeting the LXR pathway. 551 Importantly, our results underscore the importance of the health of RPE cells, located at an 552 important interface to regulate delivery of cholesterol to the retina as well as its elimination, 553 highlighting their importance as a target for ocular pathologies governed by excessive lipid 554 accumulation in the posterior pole (84) . Broadly, this translational study supports developing LXR 555 targeted therapies for the treatment of neurodegenerative diseases of aging, in which altered 556 cellular metabolism and chronic inflammation may play a role. 
